CHECKMATE-9DW

NCT04039607 📎

Regimen

Experimental
nivolumab 1 mg/kg + ipilimumab 3 mg/kg Q3W x4, then nivolumab 480 mg Q4W
Control
investigator's choice lenvatinib or sorafenib

Population

Unresectable hepatocellular carcinoma, Child-Pugh A, ECOG 0/1, no prior systemic therapy

Key finding

mOS 23.7 vs 20.6 mo (HR 0.79, 95% CI 0.65-0.96, p=0.018); early hazard crossing — first 6 mo HR 1.65 (worse) then HR 0.61 (better); 24-mo OS 49% vs 39%, 36-mo 38% vs 24%; 12 TRAE deaths vs 3 — **doubled treatment-related mortality** warrants careful patient selection; etiology HBV ~35%, HCV ~26%, non-viral ~39%

Source: PMID 40349714

Timeline

    Guideline citations

    • NCCN HCC (p.6)